Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CALT Stock Alerts

Calliditas Therapeutics AB (publ) (CALT) Competitors

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 07/17/2026
Compare

CALT vs. VKTX, CRNX, ACAD, TNGX, and EWTX

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? MarketBeat compares Calliditas Therapeutics AB (publ) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calliditas Therapeutics AB (publ) include Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), ACADIA Pharmaceuticals (ACAD), Tango Therapeutics (TNGX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry.

How does Calliditas Therapeutics AB (publ) compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Viking Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Viking Therapeutics' return on equity of -71.31% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -71.31% -65.35%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Viking Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$359.64M-$4.14N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

In the previous week, Viking Therapeutics had 11 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 11 mentions for Viking Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Viking Therapeutics' average media sentiment score of 0.28 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Viking Therapeutics Neutral
Calliditas Therapeutics AB (publ) Neutral

Viking Therapeutics presently has a consensus price target of $93.60, suggesting a potential upside of 157.28%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Viking Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

Viking Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Crinetics Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals-2,747.18% -43.96% -39.61%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Crinetics Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Crinetics Pharmaceuticals' average media sentiment score of 0.08 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Crinetics Pharmaceuticals Neutral
Calliditas Therapeutics AB (publ) Neutral

Crinetics Pharmaceuticals currently has a consensus target price of $78.27, indicating a potential downside of 6.67%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.29
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Crinetics Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$7.70M1,148.47-$465.32M-$5.13N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Summary

Crinetics Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to ACADIA Pharmaceuticals?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
ACADIA Pharmaceuticals 34.30%9.61%7.07%

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
ACADIA Pharmaceuticals Positive

ACADIA Pharmaceuticals has a consensus price target of $32.94, indicating a potential upside of 31.29%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ACADIA Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.65

ACADIA Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
ACADIA Pharmaceuticals$1.07B4.01$391M$2.2011.40

Summary

ACADIA Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 14 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Tango Therapeutics?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 53.06%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tango Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, Tango Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Tango Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Tango Therapeutics' average media sentiment score of 0.35 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Tango Therapeutics Neutral

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Tango Therapeutics' return on equity of -41.54% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Tango Therapeutics N/A -41.54%-33.44%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
Tango Therapeutics$62.38M63.86-$101.59M-$0.83N/A

Summary

Tango Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Edgewise Therapeutics presently has a consensus price target of $48.75, suggesting a potential upside of 25.61%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$167.79M-$1.66N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Edgewise Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Edgewise Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Edgewise Therapeutics' return on equity of -32.55% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -32.55% -31.04%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Edgewise Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Edgewise Therapeutics' average media sentiment score of 0.66 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Edgewise Therapeutics Positive
Calliditas Therapeutics AB (publ) Neutral

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Edgewise Therapeutics beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALT vs. The Competition

Export
MetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.19B$802.20M$6.89B$12.28B
Dividend YieldN/A4.84%2.67%9.39%
P/E Ratio-21.621.5027.0723.94
Price / Sales0.74111.87512.7190.33
Price / CashN/A22.0526.6847.25
Price / Book37.748.6710.636.14
Net Income-$43.96M-$3.14M$3.60B$331.74M
7 Day PerformanceN/A-2.97%-1.24%-1.82%
1 Month PerformanceN/A0.74%1.09%-1.45%
1 Year PerformanceN/A28.18%23.66%16.32%

Calliditas Therapeutics AB (publ) Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat		N/AN/A$1.19B$1.60BN/A180
VKTX
Viking Therapeutics
3.1072 of 5 stars		$42.13
+8.8%		$93.60
+122.2%		+13.7%$4.49BN/AN/A20
CRNX
Crinetics Pharmaceuticals
1.2919 of 5 stars		$83.53
+98.7%		$78.27
-6.3%		+169.6%$4.43B$7.70MN/A210
ACAD
ACADIA Pharmaceuticals
4.7961 of 5 stars		$26.20
+1.7%		$32.94
+25.7%		+11.2%$4.41B$1.07B11.91510
TNGX
Tango Therapeutics
2.5351 of 5 stars		$30.12
+0.6%		$41.50
+37.8%		+306.8%$4.33B$62.38MN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel